Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA non-small cell lung cancer and stage III colon cancer MRD testing helps clinicians track a patient's risk ...
Labcorp added to its suite of tests designed to detect cancer recurrence much earlier than traditional imaging.
Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...
Clinical lab and life science services company LabCorp has signaled its latest consumer-focused shift with the announcement of a self-administered wellness test and online results portal. Called Pixel ...
FIT outperformed cfDNA in detecting advanced precancerous colorectal lesions, showing higher sensitivity and specificity. Blood-based tests offer easier implementation and potentially higher adherence ...
The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...
Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results